{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:34:25Z","timestamp":1793932465372,"version":"4.8.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> An elevated heart rate is associated with an increased risk of death or cardiac transplant in children with dilated cardiomyopathy (DCM). Whether heart rate is a clinical marker to address therapy, is poorly investigated in children.<\/jats:p><jats:p><jats:bold>Aim:<\/jats:bold> To investigate the relationship between heart rate reduction (HRR) and left ventricular ejection fraction (LVEF) in DCM, treated with carvedilol.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This is a multi center retrospective analysis conducted on all children with DCM (aged &amp;lt;18\u00a0years) between 2013 and 2020, with LVEF &amp;lt;40% and treated with carvedilol. Carvedilol was up titrated to the maximal tolerated dose or to 1\u00a0mg\/kg\/day. Echocardiographic data on left ventricular function and dimension were collected. The relationship between HRR and LVEF, left ventricular end-diastolic (LVEDd) and end-systolic diameter (LVESd) was assessed before and after HRR with carvedilol, using regression analysis.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 100 patients were enrolled (M: 51%; age 7 \u00b1 8\u00a0years). The mean LVEF was 30.2 \u00b1 10% before treatment and 43.7 \u00b1 9.6% after treatment, at the maximum therapeutic dose (<jats:italic>p<\/jats:italic> &amp;lt; 0.0001). There was a positive relationship between HRR and increase in LVEF (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup> = 0.06, <jats:italic>p<\/jats:italic> = 0.014). A HRR of &amp;gt;20% correlated with an improvement in LVEF &amp;gt;13%. At 3\u00a0years follow up, HRR demonstrated a significant reduction of LVESd (R2 = 0.1, <jats:italic>p<\/jats:italic> = 0.003) LVEDd (R2 = 0.07, <jats:italic>p<\/jats:italic> = 0.008) and LVEF recovery up to 15% (<jats:italic>p<\/jats:italic> &amp;lt; 0.0001). No deaths or heart transplant occurred during follow-up.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study demonstrates that HRR is safe and improvement in LVEF is related to the degree of HRR. The magnitude of LVEF improvement was enhanced by a major reduction in HR. It provides evidence that HRR could be used as a clinical marker to treat HF in children.<\/jats:p>","DOI":"10.3389\/fphys.2022.1001752","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T07:05:00Z","timestamp":1669964700000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Heart rate reduction as a marker to optimize carvedilol treatment and enhance myocardial recovery in pediatric dilated cardiomyopathy"],"prefix":"10.3389","volume":"13","author":[{"given":"Rachele","family":"Adorisio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pontrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Cantarutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bellettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Caiazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Mencarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Limongelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Amodeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jacc.2017.07.725","article-title":"Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure","volume":"70","author":"Bonnet","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.amjcard.2007.11.023","article-title":"Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers","volume":"101","author":"Flannery","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jacc.2007.04.079","article-title":"Heart Rate Working GroupResting heart rate in cardiovascular disease","volume":"50","author":"Fox","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1067\/mhj.2002.121265","article-title":"Carvedilol therapy in pediatric patients with congestive heart failure: A study investigating clinical and pharmacokinetic parameters","volume":"143","author":"L\u00e4er","year":"2002","journal-title":"Am. Heart J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s003950050243","article-title":"Beta-blocker treatment in heart failure. Role of heart rate reduction","volume":"93","author":"Lechat","year":"1998","journal-title":"Basic Res Cardiol Suppl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: Beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Carvedilol prospective randomized cumulative survival study GroupEffect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.cir.0000035653.72855.bf","article-title":"Carvedilol prospective randomized cumulative survival (COPERNICUS) study GroupEffect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1161\/01.cir.98.12.1184","article-title":"Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of double-blind placebo-controlled randomized trials","volume":"98","author":"Packer","year":"1998","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/eurheartj\/ehv727","article-title":"Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases","volume":"37","author":"Pinto","year":"2016","journal-title":"Eur. Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00246-012-0306-8","article-title":"The Ross classification for heart failure in children after 25 years: A review and an age-stratified revision","volume":"33","author":"Ross","year":"2012","journal-title":"Pediatr. Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e015916","DOI":"10.1161\/JAHA.119.015916","article-title":"Elevated heart rate and survival in children with dilated cardiomyopathy : A multicenter study from the pediatric cardiomyopathy Registry","volume":"9","author":"Rossano","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1001\/jama.298.10.1171","article-title":"Pediatric carvedilol study GroupCarvedilol for children and adolescents with heart failure: A randomized controlled trial","volume":"298","author":"Shaddy","year":"2007","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"SHIFT InvestigatorsIvabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.1001752\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T07:05:02Z","timestamp":1669964702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.1001752\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":16,"alternative-id":["10.3389\/fphys.2022.1001752"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2022.1001752","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"article-number":"1001752"}}